Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 2 days agoThose products could range from RSV vaccines to individualized cancer treatments, which will help...
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 56 minutes agoModerna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript May 2, 2024 Moderna, Inc. beats...
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 4 days agoKey Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe company reaffirmed anticipated revenue of $4bn from its respiratory franchise. It now expects around $0.3bn in net sales for the first half of the...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 2 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 2 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 2 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 2 days agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 2 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 2 days agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to...